Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)

Awarded

75A50126C00010Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract, solicitation number 75A50126C00010, is an award notice from the Department of Health and Human Services through BARDA. The agreement utilizes Project Bioshield funds to support the late-stage clinical development and regulatory approval of 2-PAM autoinjectors. These drug-device combination products are designed to treat organophosphate poisoning, including exposure to nerve agents, for both adult and pediatric populations. In addition to development and approval, the contract covers the procurement of these autoinjectors for the SNS/CHEMPACK Program. The project is managed by the Barda - Aspr / Daappo / Barda Dcma office based in Washington, DC, with performance taking place within the District of Columbia. Primary oversight is provided by Contracting Officer Erin Greninger.

General Info

BARDA funds 2-PAM autoinjector development, regulatory approval, and procurement for CHEMPACK Program.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contract Value

$96,058,494

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Washington, DC, 20024, USA

Set-Aside

NONE

Awardee

Award Issued Date

09/30/2026, 12:00:00 AM UTC

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded

PostedSep 30

Award Notice

AwardedSep 30

Contract was awarded

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contacts2 people available

OfficeWASHINGTON, DC, 20515, USA

Organization / AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Office AddressWASHINGTON, DC, 20515, USA

Contacts

Erin Greninger Contracting Officer

contact@example.gov

Greg Smith

contact@example.gov

Full Description

Show more

This acquisition will allow BARDA to invest Project Bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

Similar Contracts

Same NAICS industry code

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

Defense Health Agency

POSTED

about 7 hours ago

DEADLINE

in about 1 month

Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-024

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for RFA-AI-28-024 to support the research and preclinical development of highly efficacious malaria vaccines. The initiative focuses on utilizing structure-based immunogen design, improved formulations, and combination vaccines to create long-lasting protection that can serve as a model for other mosquito-borne diseases. This funding opportunity is structured as a phased award, consisting of an R61 exploratory phase for up to three years with annual direct costs up to 400,000 dollars, and an R33 development phase for up to two years with annual direct costs up to 750,000 dollars. The maximum total project period is five years, and clinical trials are strictly prohibited. Applications will be evaluated through the NIH peer review system based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key requirements include the establishment of quantifiable R61 transition milestones and clear translational Go/No-go criteria for vaccine candidates. Applicants must maintain active SAM registration and provide a Data Management and Sharing Plan. Additionally, recipients must adhere to strict cybersecurity protocols modeled after the NIST framework, including multifactor authentication and a 48-hour incident notification requirement, and ensure all research involving human subjects or vertebrate animals complies with federal regulations and ethical guidelines.

National Institutes Of Health

POSTED

DEADLINE

High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.

National Institutes Of Health

POSTED

DEADLINE

Specialized Phenotypic Assay Development/ExecutionThis subcontract, titled Specialized Phenotypic Assay Development/Execution, supports prime contractors on NIH IGVF Consortium projects under the Department of Health and Human Services. The primary objective is the collection of robust phenotypic data through the execution of imaging, proteomics, and transcriptomics assays designed to measure the impacts of variant interactions. To achieve this, the contractor will utilize advanced technical equipment, including mass spectrometers, flow cytometers, and high-content imaging systems. The scope of work emphasizes the delivery of high-quality phenotypic data sets while adhering to strict quality control standards for high-throughput data. This opportunity falls under NAICS code 541714 and was posted on October 9, 2026, with a response deadline of December 14, 2026.

National Institutes Of Health

POSTED

DEADLINE

Senescence-Specific Reagent and Tool ManufacturingThis subcontract, titled Senescence-Specific Reagent and Tool Manufacturing, supports National Institutes of Health projects focused on senescence technologies. The selected provider will develop and supply innovative reagents, biospecimens, and tools for prime contractors, specifically focusing on the creation of markers for phenotypic identifiers and the manufacture of reagents to identify senescence heterogeneity within secretomes and tissue environments. The scope of work requires the use of biotechnology laboratory facilities for antibody production and protein synthesis, with a final delivery of validated assays and physical reagents. All operations must strictly adhere to NIH guidelines regarding human systems. The opportunity was posted on October 9, 2026, with a response deadline of November 23, 2026, falling under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)

Solicitation # RFA-RM-27-007

The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)

Solicitation # RFA-HG-27-008

The National Human Genome Research Institute (NHGRI), under the Department of Health and Human Services, is soliciting applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) via solicitation RFA-HG-27-008. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive, searchable catalog of genomic function and variant impacts and managing a data portal for housing and sharing consortium resources. Key technical objectives include the hardening of data processing pipelines to ensure they are containerized, robust, and reproducible, while adopting existing data and metadata standards to promote interoperability. The NHGRI intends to commit 6 million dollars in total costs for the period of FY 2027-2031, with annual application budgets limited to 4 million dollars in direct costs. Funding decisions are based on scientific peer review and program-specific considerations, focusing on technical merit, synergy with other IGVF projects, and the applicant's capability to coordinate large-scale genomic data efforts. Applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov, and all Principal Investigators must have a linked ORCID ID. Special requirements include a dedicated Project Manager devoting at least 6 person months and strict adherence to the Cybersecurity Act of 2015, which mandates reporting cybersecurity incidents within 48 hours of discovery. Proposals must include a Research Strategy limited to 30 pages and be submitted via an institutional system-to-system solution by the December 14, 2026, deadline.

National Institutes Of Health

POSTED

DEADLINE

Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-RM-27-016

The National Institutes of Health (NIH) is soliciting applications under RFA-RM-27-016 to establish SenNet Discovery and Validation Centers (DVCs) as part of Stage 2 of the Cellular Senescence Network. The primary objective of these centers is to define, refine, and validate tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. DVCs are required to investigate the functional consequences of these signatures in human health and disease, generate high-quality molecular, cellular, and spatial datasets for public release via the Data Coordination and Informatics Center, and execute consortium-wide organizational and outreach activities. The maximum project period is five years, with application budgets limited to approximately 3 million dollars in direct costs per year. A specific requirement includes a mandatory 600,000 dollar annual direct cost allocation for the SenNet Organization and Outreach Component, of which 40 to 45 percent must support educational programs. Additionally, starting in Year 2, centers must set aside approximately 10 percent of their total budget for cross-consortium validation. Applications are evaluated through the NIH peer review system based on significance, approach, and the protection of human subjects, with performance measured annually by the successful acceptance and public release of data. Applicants must maintain active registrations in the System for Award Management and eRA Commons. Required submission materials include a 30-page application divided into four elements covering vision, preclinical modeling, biospecimen management, and outreach, along with letters of support and human subjects documentation where applicable. Awardees must adhere to strict data security protocols, including a seven-year confidentiality disclosure agreement and a requirement to report cybersecurity incidents within 48 hours.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-HG-27-007

The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications under RFA-HG-27-007 to establish centers for the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to characterize genomic variation and assess how individual variants in DNA, RNA, or protein-coding elements impact genome function and phenotypes. Funded centers will utilize high-throughput methods to perturb variants, collect molecular and cellular data, and develop portable data processing pipelines. These centers are expected to collaborate within the consortium to coordinate assays and cell types, contributing raw and processed data to the IGVF Catalog via the Data Analysis and Coordination Center. The funding cycle runs from 2027 through fiscal year 2031, with a maximum project period of five years and budgets limited to 2 million dollars in direct costs per year. Notably, 20 percent of direct costs must be allocated to support collaborative work. Applications are evaluated based on scientific merit through the NIH peer review system and a second level of review by the National Advisory Council for Human Genome Research, focusing on significance, overall impact, and the utility of the proposed assays. Clinical trials are not allowed, and research involving human subjects must comply with 45 CFR Part 46. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required submissions include a Research Strategy limited to 30 pages, a Resource Sharing Plan, and a Data Management and Sharing Plan. Key personnel requirements include a minimum of three person-months of effort for the PD/PI and a dedicated Project Manager committing at least four person-months. Additionally, awardees must implement a cybersecurity incident response plan with a 48-hour notification requirement for any discovered incidents.

National Institutes Of Health

POSTED

DEADLINE

Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-HG-27-009

Solicitation RFA-HG-27-009 is a Notice of Funding Opportunity from the National Institutes of Health, under the Department of Health and Human Services, for a UM1 Research Project with Complex Structure Cooperative Agreement. The program seeks to establish interaction centers to study how genetic or environmental interactions modify genomic variant impact as part of the second phase of the Impact of Genomic Variation on Function (IGVF) Consortium. Awardees must develop a quantitative research framework to detect joint effects beyond additive modifiers, apply genomic perturbation methods to collect phenotypic data, and share all resulting data, analyses, and predictive methods through the IGVF portal and catalog. The initiative is designed as discovery science to improve the understanding of genome-wide association studies and polygenic scores. Eligible applicants include small businesses and other for-profit organizations, with a maximum project period of five years and a budget limit of 1.5 million dollars in direct costs per year. Applications are due by December 14, 2026, and are evaluated via the NIH peer review system based on significance, contribution to consortium goals, and the rigor of the proposed research. Key requirements include a dedicated Project Manager devoting at least four person months and a PD/PI effort of at least three person months. Additionally, awardees must comply with strict cybersecurity incident reporting guidelines, maintain active SAM and eRA Commons registrations, and adhere to federal regulations regarding human subjects and vertebrate animal research.

National Institutes Of Health

POSTED

DEADLINE

Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)

Solicitation # RFA-HG-27-010

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications through RFA-HG-27-010 for the Computational Modeling and Analysis of the Impact of Genomic Variation on Function initiative. This UM1 Research Project with Complex Structure Cooperative Agreement seeks to establish centers that will join the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to develop, apply, and test interpretable computational models that utilize biological, biochemical, and biophysical mechanistic information to determine how genomic variation affects genome function and phenotypes related to human health. Awardees are expected to produce open-source software, models, and documentation, while sharing predictions and integrative analyses via the IGVF catalog and data portal. The maximum project period is five years, with application budgets limited to 800,000 dollars in direct costs. A critical requirement is that 20 percent of direct costs must be allocated annually to support collaborative work. Personnel requirements include a minimum aggregate effort of three person months for PD/PIs and a dedicated Project Manager devoting at least four person months. Applications are evaluated via the NIH peer review system based on significance, investigators, innovation, approach, and environment, with a focus on the likelihood of exerting a sustained influence on the research field. Eligible applicants include small businesses and other for-profit organizations, provided they maintain active SAM registration and a Unique Entity Identifier. All awards are administered under 42 CFR Part 52 and 2 CFR Part 200.

National Institutes Of Health

POSTED

DEADLINE

Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)

Solicitation # RFA-RM-27-016

The National Institutes of Health is seeking applications for the Cellular Senescence Network Discovery and Validation Centers under solicitation RFA-RM-27-016. This initiative represents Stage 2 of the SenNet program, focusing on the definition, refinement, and validation of tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. Selected centers will investigate the functional consequences of these signatures on human health and disease while generating high-quality molecular, cellular, and spatial datasets to be shared with the broader scientific community. Awardees are expected to utilize complementary experimental systems to validate biomarkers and analyze responses to senotherapeutic approaches or senescence-associated perturbations. In addition to research goals, applicants must propose specific aims for consortium-wide organizational and outreach activities. Interested parties must submit their responses by the deadline of November 24, 2026.

POSTED

DEADLINE

in about 1 month

More opportunities from Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Same awarding agency

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The primary objective is to maintain a permanent readiness posture and commercially sustainable warm-base production capacity for the rapid manufacture of vaccines, antigens, and adjuvants during public health emergencies. Selected contractors will be responsible for producing countermeasures against influenza and other viruses with pandemic potential, generating necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data for FDA submission, and preparing candidate vaccine viruses. To be eligible, offerors must demonstrate successful experience in influenza vaccine manufacturing, evidenced by holding a U.S. influenza vaccine license or having submitted a Biologics License Application to the FDA. The contract is structured as an IDIQ with a five-year base period and a five-year option, totaling a potential 120-month ordering period. Award decisions will be based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology, with a critical requirement for offerors to achieve a High Confidence rating in capabilities. Key deliverables include the submission of comprehensive manufacturing and supply chain continuity plans, surge readiness assessments, and strict adherence to CGMP guidelines and ASPR security requirements. Performance is monitored through a BARDA dose tracker, and final acceptance is contingent upon the submission of final reports and verified temperature control documentation during delivery. Invoicing is conducted quarterly via the Department of Treasury Invoice Processing Platform.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 1 month

Vaccine Lot Production (Research, Investigational, and Commercial)This subcontract involves the production of influenza vaccine antigens and vaccines across research, investigational, and commercial bulk scales to support prime contractors on BARDA pandemic preparedness projects. The work is performed within cGMP compliant facilities to ensure all investigational and commercial lots meet strict regulatory alignment and quality standards. Managed by the Department of Health and Human Services under the Barda agency, the contract focuses on delivering bulk vaccine lots across three distinct production scales. The opportunity is categorized under NAICS code 325412, with a response deadline set for October 30, 2026, and performance based in Washington.

Pharmaceutical Preparation Manufacturing

POSTED

about 2 months ago

DEADLINE

cGMP Vaccine Seed Lot ManufacturingThis subcontract for cGMP Vaccine Seed Lot Manufacturing involves the production of yield-optimized Master Virus Seed, Working Virus Seed lots, or bacterial cell banks to support BARDA pandemic preparedness projects. The work is performed for prime contractors using qualified CVV reference strains within cGMP certified facilities that align with FDA-licensed vaccines or submitted BLAs. All seeds are characterized according to qualified internal standard operating procedures to ensure the delivery of certified lots. Managed by the Department of Health and Human Services under Barda, the contract falls under NAICS code 325412. The performance location is based in Washington, DC, with a response deadline of October 30, 2026.

Pharmaceutical Preparation Manufacturing

POSTED

about 2 months ago

DEADLINE

Candidate Vaccine Virus (CVV) Development & CharacterizationThis subcontract, titled Candidate Vaccine Virus Development and Characterization, supports BARDA pandemic preparedness projects by preparing and characterizing both non-GLP and GLP influenza Candidate Vaccine Viruses. The scope of work includes performing HA/NA sequencing, genetic stability testing, ferret pathogenicity, two-way antigenicity, HA titer, sterility, and exclusivity. Additionally, the contractor is responsible for conducting plaque assays and chicken embryo lethality for HPAI strains within a BSL-2 environment, culminating in the delivery of final reports and Certificates of Analysis or Compliance. Managed by the Department of Health and Human Services under the Barda - Aspr agency, the project is categorized under NAICS code 541714. The performance location is based in Washington, DC. The solicitation was posted on August 17, 2026, with a response deadline set for October 30, 2026.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 2 months ago

DEADLINE

Specialized Material Supply (Vials, Stoppers, Seals)This subcontract for Specialized Material Supply focuses on providing critical medical-grade components, including vials, stoppers, seals, and crimps, to support prime contractors on BARDA pandemic preparedness projects. The scope of work requires the delivery of physical inventory and the provision of comprehensive supply chain narratives that detail the country of origin and tariff exposure for all containment and closure materials. Managed by the Department of Health and Human Services under the agency Barda - Aspr / Daappo / Barda Dcma, the contract is categorized under NAICS code 326199. The place of performance is located in Washington, DC, with a response deadline set for October 30, 2026.

All Other Plastics Product Manufacturing

POSTED

about 2 months ago

DEADLINE

Labeling, Packaging, and Cold Chain StorageThis subcontract, managed by the Department of Health and Human Services under BARDA, focuses on providing essential labeling, packaging, and specialized stability storage for bulk and final vaccine products. The scope of work involves supporting prime contractors on pandemic preparedness projects by managing cold chain logistics and stability monitoring for commercial scale bulk antigens, final containers, and bulk adjuvants. The contractor is responsible for the delivery of packaged products and the provision of detailed stability reports. This opportunity is categorized under NAICS code 493110 and is based in Washington, DC. The response deadline for this requirement is October 30, 2026.

General Warehousing and Storage

POSTED

about 2 months ago

DEADLINE

Formulation, Filling, and Finishing ServicesThis subcontract for Formulation, Filling, and Finishing Services supports BARDA pandemic preparedness projects by providing final formulation and filling of antigens, adjuvants, or co-formulated products into final containers. The work is performed under cGMP compliant processes within sterile filling environments to ensure the delivery of high-quality filled vials and containers for prime contractors. The opportunity is managed by the Department of Health and Human Services under the Barda - Aspr / Daappo / Barda Dcma agency and is categorized under NAICS code 325412. The project is based in Washington, DC, with a response deadline of October 30, 2026.

Pharmaceutical Preparation Manufacturing

POSTED

about 2 months ago

DEADLINE

cGMP Adjuvant ManufacturingThis subcontract, titled cGMP Adjuvant Manufacturing, involves the production of clinical or commercial scale bulk lots of vaccine adjuvants to support BARDA pandemic preparedness projects. The primary objective is to manufacture these adjuvants within cGMP certified facilities to enhance the efficacy of influenza vaccines as part of United States Government efforts. The contract is managed by the Department of Health and Human Services under the agency Barda - Aspr / Daappo / Barda Dcma, with the place of performance located in Washington. The solicitation was posted on August 17, 2026, with a response deadline of October 30, 2026, and falls under NAICS code 325412.

Pharmaceutical Preparation Manufacturing

POSTED

about 2 months ago

DEADLINE

Animal Model Development for Phosphine & Cyanide ExposureThis contract involves the development and validation of animal models designed to accurately replicate human exposure to phosphine and cyanide. These models are intended to be used for testing medical countermeasures under the FDA Animal Rule, which provides regulatory pathways for drugs and biologics when human trials are not ethical or feasible. The work falls under the subcontract category and is associated with the Department of Health and Human Services, specifically managed by BARDA (Biomedical Advanced Research and Development Authority) and affiliated offices. The focus of the effort is to create reliable and scientifically robust animal models that can simulate the toxicological and pharmacological effects of phosphine and cyanide exposure in humans. This will facilitate the evaluation and approval of medical treatments aimed at counteracting these toxic agents in emergency or threat scenarios. The contract aligns with NAICS code 541715, which involves research and development in the physical, engineering, and life sciences sectors. The solicitation was posted in April 2026, and although specific details on location and points of contact are not provided, the contract is accessible through official government procurement platforms.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Expanded Biological Sample Analysis (Toxicology & Biomarkers)The contract involves the comprehensive analysis of biological samples, including blood, serum, and urine, to identify toxicological markers, conduct metabolomic profiling, and gather pharmacokinetic data. This work is aimed at assessing the safety and efficacy of medical countermeasures (MCM), supporting efforts to ensure that these interventions meet required safety standards and perform effectively in relevant scenarios. The contract falls under the NAICS code 541620, which relates to environmental consulting services, indicating specialized scientific and analytical work. Awarded by the Department of Health and Human Services through the Biomedical Advanced Research and Development Authority (BARDA), the subcontract focuses on advanced biological sample analysis as part of ongoing health protection initiatives. Although specific solicitation and contact details are not provided, the contract was posted in April 2026 and is intended to bolster toxicological and biomarker research critical to public health preparedness and response efforts. The work is conducted under the oversight of BARDA programs, underscoring its strategic importance in developing therapeutic and diagnostic solutions.

Environmental Consulting Services

POSTED

DEADLINE

In Vivo Imaging and Data Acquisition (Preclinical)This contract involves conducting in vivo preclinical imaging using modalities such as MRI, CT, and PET to study live animal models during nonclinical investigations. The goal is to evaluate physiological responses to various chemical agents and medical countermeasures, supporting the assessment and development of these substances. The contract is issued as a subcontract under the NAICS code 541380 and is managed by the Department of Health and Human Services through its bureaus including BARDA and ASPR. The contract emphasizes data acquisition and analysis in preclinical settings, playing a critical role in advancing medical research and product development aimed at improving public health preparedness and response. The location details and point of contact information were not specified, but the contract was posted on April 22, 2026, reflecting ongoing efforts to support nonclinical study capabilities in biomedical research.

Testing Laboratories and Services

POSTED

DEADLINE

Tissue Collection, Processing, and HistopathologyThis contract involves the collection, preservation, sectioning, and histological analysis of animal tissues following exposure to chemical agents and medical countermeasures (MCMs). The purpose is to support toxicology and efficacy assessments, ensuring thorough examination of tissue responses to these substances. The scope includes detailed processing and microscopic evaluation to provide critical data for understanding the biological effects and safety profiles of the tested agents. Issued by the Department of Health and Human Services under the BARDA-ASPR/DAAPO/BARDA DCMA umbrella, this subcontract falls under the NAICS code 541611, indicating professional, scientific, and technical services. The contract was posted on April 22, 2026, and although specific location details and points of contact are not provided, it is structured to facilitate specialized laboratory analysis essential for public health preparedness and response initiatives.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS